Literature DB >> 25216799

TOX expression in different subtypes of cutaneous lymphoma.

Sohshi Morimura1, Makoto Sugaya, Hiraku Suga, Tomomitsu Miyagaki, Hanako Ohmatsu, Hideki Fujita, Yoshihide Asano, Yayoi Tada, Takafumi Kadono, Shinichi Sato.   

Abstract

Early cutaneous T cell lymphoma clinically and histologically resembles benign inflammatory skin diseases, which sometimes makes it difficult to reach a correct diagnosis. It is recently reported that thymocyte selection-associated high mobility group box factor (TOX) serves as a molecular marker for histological diagnosis of early-stage mycosis fungoides (MF). To examine whether TOX could be a marker of tumour cells in different types of cutaneous lymphoma, we investigated immunohistochemical staining for TOX with the lesional skin of patch, plaque, and tumour MF, Sézary syndrome (SS), lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (PCALCL), adult T cell leukemia/lymphoma (ATLL), peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), atopic dermatitis (AD), and normal skin. TOX and CCR4 messenger RNA (mRNA) levels in lesional skin of MF/SS were also examined. Immunohistological staining showed that a high specific nuclear staining of TOX was observed at a high frequency in MF, SS, and PTCL, NOS. Tumour cells in LyP, PCALCL, and ATLL showed a slightly dim nuclear staining of TOX. TOX(+) cells in MF and LyP expressed surface molecules characteristics of tumour cells in these diseases. Lesional skin of SS expressed higher levels of TOX mRNA, compared to normal skin or MF lesional skin. Moreover, TOX expression significantly correlated with CCR4 expression. TOX may be a specific marker for tumour cells in some types of cutaneous lymphoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25216799     DOI: 10.1007/s00403-014-1501-7

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  14 in total

1.  CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.

Authors:  Bernice M Benoit; Neha Jariwala; Geraldine O'Connor; Landon K Oetjen; Timothy M Whelan; Adrienne Werth; Andrea B Troxel; Hélène Sicard; Lisa Zhu; Christopher Miller; Junko Takeshita; Daniel W McVicar; Brian S Kim; Alain H Rook; Maria Wysocka
Journal:  Arch Dermatol Res       Date:  2016-10-20       Impact factor: 3.017

Review 2.  Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.

Authors:  Sara Berg; Jennifer Villasenor-Park; Paul Haun; Ellen J Kim
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

3.  TOX expression and role in CTCL.

Authors:  L Y McGirt; C A Degesys; V E Johnson; J A Zic; J P Zwerner; C M Eischen
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-26       Impact factor: 6.166

Review 4.  TOX gene: a novel target for human cancer gene therapy.

Authors:  Xin Yu; Zheng Li
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

5.  Increased Expression of Delta-like Ligand 4 in Mycosis Fungoides.

Authors:  Hikari Boki; Tomomitsu Miyagaki; Yuki Shono; Hiroaki Kamijo; Tomonori Oka; Hiraku Suga; Yoshihide Asano; Makoto Sugaya; Shinichi Sato
Journal:  Acta Derm Venereol       Date:  2020-02-25       Impact factor: 3.875

6.  TOX acts an oncological role in mycosis fungoides.

Authors:  Xin Yu; Yixin Luo; Jie Liu; Yuehua Liu; Qiuning Sun
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 7.  Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.

Authors:  Alexandra Ion; Iris Maria Popa; Laura Maria Lucia Papagheorghe; Cristina Lisievici; Mihai Lupu; Vlad Voiculescu; Constantin Caruntu; Daniel Boda
Journal:  Dis Markers       Date:  2016-10-16       Impact factor: 3.434

8.  NLRP3 Regulates IL-4 Expression in TOX+ CD4+ T Cells of Cutaneous T Cell Lymphoma to Potentially Promote Disease Progression.

Authors:  Enrique Huanosta-Murillo; Marcela Alcántara-Hernández; Brenda Hernández-Rico; Georgina Victoria-Acosta; Patricia Miranda-Cruz; María Antonieta Domínguez-Gómez; Fermín Jurado-Santacruz; Genaro Patiño-López; Vadim Pérez-Koldenkova; Alam Palma-Guzmán; Paula Licona-Limón; Ezequiel M Fuentes-Pananá; Alicia Lemini-López; Laura C Bonifaz
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

9.  TOX expression in cutaneous B-cell lymphomas.

Authors:  Anne M R Schrader; Patty M Jansen; Rein Willemze
Journal:  Arch Dermatol Res       Date:  2016-05-14       Impact factor: 3.017

10.  Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.

Authors:  Jingkai Xu; He Huang; Shangshang Wang; Yanzhen Chen; Xueli Yin; Xuejun Zhang; Yaohua Zhang
Journal:  Arch Dermatol Res       Date:  2019-11-01       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.